Skye Bioscience, Inc. Advances, Fair Value Disclosure
Skye Bioscience, Inc. (SKYE) had Advances, Fair Value Disclosure of $1.88 million as of 2019-12-31, per its 10-Q filed 2020-11-06.
Discontinued › Notes
us-gaap:AdvancesFairValueDisclosure · last filed 2020-11-06
- 2019-12-31: Advances, Fair Value Disclosure $1.88M.
| Period end | Advances, Fair Value Disclosure |
|---|---|
| 2019-12-31 | $1.88M 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |